Core Viewpoint - Inspire Medical Systems, Inc. is under investigation by Kahn Swick & Foti, LLC due to potential breaches of fiduciary duties and failure to disclose material information related to the launch of its Inspire V device [1][3]. Group 1: Company Issues - In August 2025, Inspire Medical Systems disclosed that the launch of its Inspire V device would face an "elongated timeframe" due to undisclosed issues, including incomplete training and onboarding at many centers, delayed software updates, and excess inventory leading to poor demand [2]. - As a result of these issues, the company significantly reduced its 2025 earnings guidance by over 80%, from a range of $2.20 to $2.30 per share to a new range of $0.40 to $0.50 per share [2]. Group 2: Legal Actions - Following the disclosure of these issues, Inspire Medical Systems and certain executives were sued in a securities class action lawsuit for failing to disclose material information, which is still ongoing [3]. - KSF's investigation is focused on whether the company's officers and/or directors breached their fiduciary duties to shareholders or violated state or federal laws [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased SLM Corporation securities between July 25, 2025, and August 14, 2025, of the February 17, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought SLM securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court by February 17, 2026, to serve as lead plaintiff, representing other class members [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 [4]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, SLM made false and misleading statements regarding its financial health, specifically concerning early-stage delinquencies and the effectiveness of its loss mitigation programs [5]. - It is claimed that these misrepresentations led to a materially false impression of SLM's business operations and prospects, resulting in investor damages when the truth was revealed [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased SLM Corporation securities between July 25, 2025, and August 14, 2025, of the February 17, 2026, deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought SLM securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lawsuit alleges that SLM made false and misleading statements regarding its financial stability and loan delinquency rates, which led to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [4].

Group 1 - The consortium is close to finalizing a deal to acquire ST Telemedia Global Data Centres, with the transaction valued at over $10 billion [1]

Core Viewpoint - The recent sell-off in Mastercard and Visa stocks presents a significant buying opportunity for long-term investors despite concerns over consumer spending and proposed interest rate caps [1]. Financial Performance - Mastercard's revenue increased by 18%, while Visa's revenue rose by 15% [4]. - Mastercard's operating income grew by 25%, with operating margins reaching 55.8% and diluted EPS increasing by 24% [4]. - Visa's operating margin was 61.8%, with non-GAAP EPS rising by 15% [4]. Market Dynamics - Both companies reported high-single-digit to low-double-digit increases in payment volume and frequency, indicating resilience in their business models [5]. - The fee structure of Mastercard and Visa is based on transaction frequency and total sales, making them somewhat recession-resistant [5]. Shareholder Returns - In 2025, Mastercard returned $11.73 billion through stock buybacks and $2.76 billion in dividends, while Visa's latest quarter saw $3.73 billion in buybacks and $1.29 billion in dividends [8]. - Both companies yield less than 1% due to a preference for buybacks over dividends, but if funds were reallocated, Mastercard could yield about 3% and Visa about 3.1% [9]. Valuation and Investment Thesis - Both stocks are considered reasonably valued based on price-to-free cash flow and forward earnings expectations [10]. - Mastercard and Visa are viewed as foundational stocks for long-term portfolios due to their strong business models and global network effects [12]. Regulatory Environment - Concerns about capping credit card interest rates at 10% may persist, but it is believed that such a low cap would lead financial institutions to restrict credit access, ultimately harming consumers [13].

Core Viewpoint - The electric vehicle (EV) industry faced challenges in 2025, but companies like Lucid Motors and Nio are showing strong momentum heading into 2026, with differing investment prospects for risk-tolerant investors [1][2]. Group 1: Nio's Performance - Nio set a new monthly record for deliveries in December, achieving a 54.6% increase to 48,135 vehicles compared to the previous year [3]. - The fourth quarter saw an impressive 71.7% year-over-year growth in deliveries, totaling 124,807 vehicles [3]. - Nio's newer brands, Onvo and Firefly, contributed to only one-third of December's deliveries, indicating potential for further growth as market reach expands [4]. - Vehicle margins and gross profits improved significantly in Q3, suggesting that Nio's growth is becoming more profitable [4]. - Nio aims for 2026 to be its first breakeven year, which would be a significant milestone for both the company and the EV industry [9]. Group 2: Lucid's Performance - Lucid produced 8,412 vehicles in Q4, marking a 116% increase year-over-year, and delivered 5,345 vehicles, a 31% increase from the prior year [5]. - Lucid has set delivery records for eight consecutive quarters, with production of the Gravity SUV accelerating after overcoming supplier bottlenecks [6]. - Despite delivery growth, Lucid continues to experience cash burn, with widening adjusted EBITDA losses, and faces challenges in its market entry into Saudi Arabia due to the Public Investment Fund's significant stake [8]. Group 3: Investment Considerations - While both Nio and Lucid show delivery momentum, Lucid's financial challenges suggest that investors should monitor its stock from the sidelines [9]. - Investments in Nio are recommended to be limited to small positions, given its improving financial metrics compared to Lucid [9].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Bath & Body Works, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on March 16, 2026 [1]. Group 1: Class Action Details - Investors who bought Bath & Body Works securities between June 4, 2024, and November 19, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lawsuit alleges that Bath & Body Works made materially false and misleading statements regarding its business strategy and financial performance, which led to investor damages when the truth was revealed [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success and recognition in the field [4]. - The firm has achieved significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Bath & Body Works, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Bath & Body Works securities between June 4, 2024, and November 19, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 16, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that Bath & Body Works made materially false and misleading statements regarding its business strategy and financial performance, which misled investors [5]. - Specific claims include the failure of the company's strategy to grow its customer base and the reliance on brand collaborations to mask weak financial results [5]. - As a result of these misleading statements, the company was unlikely to meet its previously issued financial guidance, leading to investor damages when the truth was revealed [5].

Company Overview - Arcellx, Inc. is a clinical-stage biotechnology company focused on innovative immunotherapies for cancer and other incurable diseases, primarily collaborating with oncology healthcare providers and patients in the U.S. and select global markets [5] - As of January 20, 2026, the company's stock price was $68.31, with a market capitalization of $3.95 billion and a revenue of $35.90 million for the trailing twelve months [4] Transaction Summary - Director David Charles Lubner sold 6,000 shares of Arcellx common stock for approximately $450,000 on January 20, 2026, reducing his direct holdings by 21.69% [1][2][8] - Post-transaction, Lubner holds 21,659 shares valued at approximately $1.56 million based on the closing price of $72.17 on the same date [2] Financial Performance - The company's stock fell approximately 15% in 2025, indicating struggles in its market performance [9] - Despite negative operating income, Arcellx has sufficient funding to operate through 2028, reflecting strong investor support [6] Development Milestones - Arcellx recently advanced its multiple myeloma treatment to the second phase of development, which could become a significant revenue generator if successful [7] Ownership and Transaction Implications - The transaction was executed under a Rule 10b5-1 prearranged plan, suggesting that the timing and scale of the sale were predetermined [8]

Core Viewpoint - Symmetry Partners, LLC has initiated a significant position in the Dimensional Global Core Plus Fixed Income ETF, acquiring 2,471,670 shares valued at approximately $133.64 million, which now represents 7.91% of their reportable assets under management [2][3][6] ETF Overview - The Dimensional Global Core Plus Fixed Income ETF provides access to a diversified range of global fixed income markets, including government, corporate, and securitized sectors [5][7] - As of January 26, 2026, the ETF has an asset under management (AUM) of $2.12 billion and a share price of $54.43 [4] - The ETF offers a trailing twelve-month dividend yield of 3.43% and a one-year total return of 5.89% [4][3] Investment Strategy - The ETF's strategy focuses on broad exposure to global investment-grade and select lower-rated debt securities, aiming for total return through diversified fixed income allocations [7][8] - The fund is actively managed, which allows for a research-focused approach rather than passive index tracking [8][9] Performance and Holdings - The ETF's performance has underperformed the S&P 500 by 7.38 percentage points over the past year, with a total return of 5.9% [3] - Despite its relatively short track record since inception in 2023, the ETF has attracted significant investment interest, indicating confidence from investors like Symmetry Partners [9][10] Investor Implications - The substantial investment by Symmetry Partners has made the Dimensional Global Core Plus Fixed Income ETF their second-largest holding, reflecting strong conviction in its potential [6][8] - The ETF may be appealing to investors seeking to complement equity holdings with steady income as part of a diversified portfolio [10]